NEW YORK (360Dx) – In situ biological imaging firm Ultivue said late Tuesday that it closed its $20 million Series B financing round.

The funding will go toward further development and commercialization of its InSituPlex technology for unbiased biomarker analysis in tissue. Initial commercialization of the technology will be directed at the translational and clinical research space "with a rapid transition into regulated in vitro diagnostics markets."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.